In This Section

Evolutionary Dynamics in Carcinogenesis and Response to Therapy

March 12-15, 2020
Westin Denver Downtown
Denver, Colorado

Conference Cochairs

James DeGregori, University of Colorado, Aurora, Colorado
Marco Gerlinger, The Institute of Cancer Research, London, United Kingdom
Robert Gillies, Moffitt Cancer Center, Tampa, Florida
Andriy Marusyk, Moffitt Cancer Center, Tampa, Florida

CORONAVIRUS UPDATE

The AACR is closely monitoring the continuing developments with the Novel Coronavirus. We want to assure anyone planning to attend any AACR meeting that their safety and security are our top priority.

Based on all available information, at this time there is no plan to cancel or postpone any of the scheduled AACR meetings.

We are following the guidance of the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) in regard to travel and event management. In addition, we are closely monitoring all travel alerts issued by the U.S. Department of Homeland Security, and recommendations and policies developed by our peer groups and other large scientific societies.

We will also take proactive steps at all our meetings, such as adding hand sanitizer stations throughout the meeting venue. We encourage attendees to monitor the CDC website for additional information and review and follow the WHO’s Travel Advice, as well as its recommendations for protecting themselves from an infection.

If you have any questions or need further information, please call AACR at +1-215-440-9300 or email meetings@aacr.org.

  • Watch this video from Conference Cochair James DeGregori:


This will mark the first AACR Special Conference on evolutionary dynamics in cancer and how these processes contribute to therapy resistance and failure. Tumors are genetically diverse and complex ecosystems that evolve in response to selection pressures from their environment. The aim of this AACR Special Conference is to move away from the simplistic view of cancer evolution as a merely genetic phenomenon and to discuss instead how microenvironmental, immune cell, genetic and epigenetic heterogeneity interact and evolve and how this influences cancer progression and therapy success or failure. By promoting the exchange of novel ideas and information between basic scientists, physicians, and other health professionals, this inaugural conference will enhance the understanding of cancer evolution and make progress toward treatment paradigms that limit therapy resistance.

PROFESSIONAL EDUCATIONAL GRANTS

AbbVie

Pfizer

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available

#AACREVD20